Acute Myeloid Leukemia Clinical Trial

Clinical Trial Finder Acute Myeloid Leukemia Trials

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

See Locations Near You

Summary

The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Untreated AML that occurred de novo, after prior exposure to chemotherapy for a separate malignancy, or evolved from an antecedent hematologic disorder.
After being informed of the potential benefits and risks of available treatment options, patients must have declined intensive chemotherapy for AML.
At least 20% blasts in blood or marrow.
Must have a minimum of 50% leukemic blasts that express CD33.
ECOG performance status score of 0 to 2.
WBC less than 30,000/µL

Exclusion Criteria:

No known diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia.
No other active systemic malignancies treated with chemotherapy within the last 12 months.
Must not have received previous chemotherapy (except hydroxyurea) for AML.
Must not have significantly abnormal kidney or liver disease.
Must not have known human immunodeficiency virus (HIV).

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

211

Study ID:

NCT00528333

Recruitment Status:

Completed

Sponsor:

Seagen Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 20 Locations for this study

See Locations Near You

Southern Cancer Center
Mobile Alabama, 36608, United States
Tower Cancer Research Foundation
Beverly Hills California, 90210, United States
Glendale Memorial Hospital
Glendale California, 91204, United States
Kenmar Research Institute
Los Angeles California, 90057, United States
University of California Los Angeles
Los Angeles California, 90095, United States
Bay Area Cancer Research Group
Pleasant Hill California, 94523, United States
University of Colorado Cancer Center
Aurora Colorado, 80045, United States
Lakeland Regional Cancer Center
Lakeland Florida, 33805, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa Florida, 33612, United States
Rush University Medical Center
Chicago Illinois, 60612, United States
Joliet Oncology-Hematology Associates
Joliet Illinois, 60435, United States
Michigan State University, Breslin Cancer Center
Lansing Michigan, 48910, United States
Billings Clinic Cancer Research
Billings Montana, 59101, United States
Northshore University Hospital, Monter Cancer Center
Lake Success New York, 11042, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States
Western Pennsylvania Cancer Institute
Pittsburgh Pennsylvania, 15224, United States
Cancer Centers of the Carolinas
Greenville South Carolina, 29601, United States
University of Texas, MD Anderson Cancer Center
Houston Texas, 77030, United States
Gunderson Clinic
La Crosse Wisconsin, 54601, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

211

Study ID:

NCT00528333

Recruitment Status:

Completed

Sponsor:


Seagen Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider